Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia.

ABSTRACT:

Purpose

Aim of this study was to analyze the safety of prostate-specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) with preexisting moderate to severe thrombocytopenia (CTCAE ≥ 2).

Materials and methods

Seventeen mCRPC patients with preexisting thrombocytopenia (platelet count < 75 × 10⁹/L) were included in this study. Patients received a median of 3 cycles of [¹⁷⁷Lu]Lu-PSMA-617 (range 1-6). The course of platelet cell count was closely monitored within and after the PSMA-RLT and analyzed statistically and according to CTCAE.

Results

No significant difference in platelet counts was observed between baseline and follow-up after each PSMA-RLT cycle: first cycle (54.18 ± 

SUBMITTER: Bastian MB 

PROVIDER: S-EPMC11839894 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature